Tirzepatide
Also known as: Mounjaro, Zepbound, LY3298176
A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials.
Mechanism of Action
Tirzepatide activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation. The dual mechanism enhances glucose-dependent insulin release while reducing glucagon and slowing gastric emptying.
Research Summary
SURMOUNT trials showed average weight loss of 20-26% body weight. SURPASS-2 showed superior A1C reduction compared to semaglutide. Demonstrates significant improvements in cardiovascular risk factors including blood pressure and lipids.
Research Protocols
Note: Prescribed doses per FDA labeling
Common Doses
- •2.5mg weekly (starting)
- •5mg weekly
- •10mg weekly
- •15mg weekly (max)
Duration
Long-term / chronic use
Administration
Subcutaneous injection weekly
Side Effects & Considerations
- •Nausea
- •Diarrhea
- •Decreased appetite
- •Vomiting
- •Constipation
- •Dyspepsia
- •Abdominal pain
- •Injection site reactions
- •Potential pancreatitis risk
References
Want updates on Tirzepatide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.